title: Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
authors.affiliation: Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Sekeres
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Swern
authors.affiliation: Service d'Hématologie Séniors, Hôpital St Louis, Université Paris 7, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.affiliation: Stanford University Cancer Center, Stanford, CA, USA.
authors.forename: P L
authors.initials: PL
authors.lastname: Greenberg
authors.affiliation: Hospital Universitario y Politécnico La Fe, Valencia, Spain.
authors.forename: G F
authors.initials: GF
authors.lastname: Sanz
authors.affiliation: University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.affiliation: Hôpital Cochin, Université Paris, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Dreyfus
authors.affiliation: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
authors.forename: A F
authors.initials: AF
authors.lastname: List
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Li
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Sugrue
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D012307:Risk Factors; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D020533:Angiogenesis Inhibitors; D013792:Thalidomide; D000077269:Lenalidomide